These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1525445)

  • 41. Effect of follicular aspiration on hormonal parameters in patients undergoing ovarian stimulation.
    Gonen Y; Powell WA; Casper RF
    Hum Reprod; 1991 Mar; 6(3):356-8. PubMed ID: 1955540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?
    Caserta D; Lisi F; Marci R; Ciardo F; Fazi A; Lisi R; Moscarini M
    Gynecol Endocrinol; 2011 Nov; 27(11):862-6. PubMed ID: 21391759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro fertilization treatment in patients with polycystic ovaries.
    Shulman A; Dor J
    J Assist Reprod Genet; 1997 Jan; 14(1):7-10. PubMed ID: 9013301
    [No Abstract]   [Full Text] [Related]  

  • 45. Prevention of ovarian hyperstimulation syndrome.
    Wiwanitkit V
    Fertil Steril; 2011 Jun; 95(8):e65; author reply e66. PubMed ID: 21530962
    [No Abstract]   [Full Text] [Related]  

  • 46. [Assisted reproduction and risks of superovulation].
    Seppälä M; Tiitinen A; Teramo K; Raivio K
    Duodecim; 1996; 112(4):245-7. PubMed ID: 10590636
    [No Abstract]   [Full Text] [Related]  

  • 47. [Overstimulation of the ovary: prevention and treatment].
    Antoine JM
    J Gynecol Obstet Biol Reprod (Paris); 2003; 32(3 Pt 2):S41-5. PubMed ID: 12773918
    [No Abstract]   [Full Text] [Related]  

  • 48. Human in vitro fertilization.
    Blasco L; Tureck R
    Ann Clin Lab Sci; 1985; 15(3):177-84. PubMed ID: 3922277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of cabergoline on folicular microenviroment profile in patients with high risk of OHSS.
    Guvendag Guven ES; Dilbaz S; Duraker R; Mentese A; Cinar O; Ozdegirmenci O
    Gynecol Endocrinol; 2013 Aug; 29(8):749-53. PubMed ID: 23741965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics of populations of granulosa cells from individual follicles in women undergoing 'coasting' during controlled ovarian stimulation (COS) for IVF.
    Tozer AJ; Iles RK; Iammarrone E; Nica RA; Gillott CM; Xusong W; Al-Shawaf T; Grudzinskas JG
    Hum Reprod; 2004 Nov; 19(11):2561-8. PubMed ID: 15471924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [In vitro oocyte maturation for safer treatment of infertility. The risk of ovarian overstimulation syndrome is minimized].
    Hreinsson J; Fridström M
    Lakartidningen; 2004 Nov; 101(46):3665-8, 3671. PubMed ID: 15586490
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormonal profiles and follicular growth in cycles with imminent ovarian hyperstimulation.
    Kushnir O; Ben-Rafael Z; Shalev J; Lipitz S; Bider D; Mashiach S; Blankstein J
    Hum Reprod; 1991 May; 6(5):665-9. PubMed ID: 1939544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of gonadotropin releasing hormone agonist following follicular aspiration in donor oocyte program--impact on subsequent menstruation.
    Ng ST; Wu TC
    Int J Fertil Menopausal Stud; 1995; 40(1):29-33. PubMed ID: 7749432
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
    D'Angelo A; Amso N
    Cochrane Database Syst Rev; 2002; (3):CD002811. PubMed ID: 12137659
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The treatment of patients with polycystic ovaries undergoing IVF.
    Franks S
    J Assist Reprod Genet; 1997 Jan; 14(1):12-4. PubMed ID: 9013303
    [No Abstract]   [Full Text] [Related]  

  • 56. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome.
    Spitzer D; Wogatzky J; Murtinger M; Zech MH; Haidbauer R; Zech NH
    Fertil Steril; 2011 Jun; 95(8):2742-4.e1. PubMed ID: 21411081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Ovarian hyperstimulation syndrome. Diagnosis and prevention are extremely important].
    Nylund L; Carlström K; Gustafson O
    Lakartidningen; 1993 Mar; 90(10):915-7. PubMed ID: 8459733
    [No Abstract]   [Full Text] [Related]  

  • 58. Induction of pre-ovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome.
    Shalev E; Geslevich Y; Ben-Ami M
    Hum Reprod; 1994 Mar; 9(3):417-9. PubMed ID: 8006128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome.
    Mansour R; Aboulghar M; Serour G; Amin Y; Abou-Setta AM
    Hum Reprod; 2005 Nov; 20(11):3167-72. PubMed ID: 16006465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.